Business
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202 into R/R AML pivotal study and evaluating indication expansion to include newly diagnosed AML and pediatric AML; Preparing for FDA discussions in the first half of 2026 SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may enable an expedited development and review
About this update from Senti Biosciences Holdings, Inc.
[{"type":"image","alt":"Senti Biosciences, Inc.","displaySize":"","headline":null,"caption":"Senti Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":166,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/4576ff302df7a498c5620f46e0596daf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LwHg6RoZ4drUhxxgTNKbZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4576ff302df7a498c5620f46e0596daf","width":166,"height":42}},"lazy":false},{"type":"text","content":"Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile","length":144,"tagName":"p"},{"type":"text","content":"Company planning for rapid advancement of SENTI-202 into R/R AML pivotal study and evaluating indication expansion to include newly diagnosed AML and pediatric AML; Preparing for FDA discussions in the first half of 2026 ","length":220,"tagName":"p"},{"type":"text","content":"SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may enable an expedited development and review process","length":142,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the completion of enrollment in its Phase 1 clinical trial evaluating SENTI-202, a first-in-class CD33/FLT3-targeting Logic Gated CAR NK cell therapy, in patients with relapsed or refractory acute myeloid leukemia (R/R AML).","length":498,"tagName":"p"},{"type":"text","content":"“The completion of enrollment in our Phase 1 trial represents a significant clinical milestone for our SENTI-202 program,” said Kanya Rajangam, M.D., Ph.D. Chief Medical Officer at Senti Bio. “Importantly, the encouraging clinical data from this study provide a strong foundation as we actively design our pivotal program for SENTI-202 in AML, as well as potential indication expansion and later-stage clinical development. We look forward to having productive discussions and working closely with the FDA in the first half of this year to discuss the next phase of development for our RMAT-designated pro...